In one of the largest med-tech M&As in recent history, Danaher (Washington) has reported that it will acquire Beckman Coulter (Brea, California), a developer of products that simplify, automate and innovate complex biomedical testing, for nearly $6.8 billion. The merger agreement would see Danaher acquiring Beckman Coulter's outstanding common stock for $83.50 per share in cash, representing an approximate 45% premium over the closing price of Beckman Coulter's common stock on Dec. 9, 2010 before rumors of an acquisition entered the marketplace. (Medical Device Daily) Read More
